We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M Turnover 0%
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+57.9%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$307M
AUM Growth
+$14.4M
Cap. Flow
-$84.4M
Cap. Flow %
-27.49%
Top 10 Hldgs %
96.9%
Holding
19
New
–
Increased
–
Reduced
1
Closed
–
Avg Time Held
3.3 years
Top 10 Avg Time Held
1.6 years
Top 20 Avg Time Held
3.3 years

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$84.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PCVX icon
1
Vaxcyte
PCVX
$10B
$96.8M 31.54%
2,019,057
-2,149,661
-52% -$84.4M
2020 Q2
10 quarters
VRNA
2
DELISTED
Verona Pharma
VRNA
$64.2M 20.92%
2,457,500
– –
2018 Q3
17 quarters
VERA icon
3
Vera Therapeutics
VERA
$2.08B
$57.3M 18.66%
2,960,231
– –
2021 Q2
6 quarters
HLVX icon
4
DELISTED
HilleVax
HLVX
$30.8M 10.02%
1,838,486
– –
2022 Q2
2 quarters
ACET icon
5
Adicet Bio
ACET
$42.4M
$18.9M 6.16%
132,212
– –
2021 Q1
7 quarters
PHAT icon
6
Phathom Pharmaceuticals
PHAT
$567M
$16.1M 5.25%
1,435,106
– –
2019 Q4
12 quarters
OKUR icon
7
OnKure Therapeutics
OKUR
$91.1M
$4.83M 1.57%
207,396
– –
2021 Q2
6 quarters
SIEN
8
DELISTED
Sientra, Inc.
SIEN
$3.4M 1.11%
167,359
– –
2014 Q4
32 quarters
JSPR icon
9
Jasper Therapeutics
JSPR
$15.9M
$2.72M 0.89%
562,856
– –
2021 Q3
5 quarters
SLNO icon
10
DELISTED
Soleno Therapeutics
SLNO
$2.38M 0.78%
1,201,506
– –
2018 Q4
16 quarters
NCNA icon
11
NuCana
NCNA
$4.07M
$2.2M 0.72%
667
– –
2020 Q3
9 quarters
EFTR icon
12
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$2.06M 0.67%
192,885
– –
2021 Q3
5 quarters
SPRB icon
13
Spruce Biosciences
SPRB
$116M
$1.97M 0.64%
23,900
– –
2022 Q3
1 quarter
PRTK
14
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$1.95M 0.63%
1,041,131
– –
2014 Q4
32 quarters
CBAY icon
15
DELISTED
Cymabay Therapeutics
CBAY
$822K 0.27%
131,036
– –
2015 Q3
29 quarters
XCUR icon
16
Exicure
XCUR
$6.74M
$324K 0.11%
56,327
– –
2019 Q3
13 quarters
SYRE icon
17
Spyre Therapeutics
SYRE
$7.92B
$108K 0.04%
9,620
– –
2019 Q1
15 quarters
MTEM icon
18
DELISTED
Molecular Templates, Inc.
MTEM
$66K 0.02%
13,333
– –
2019 Q4
12 quarters
OBSV
19
DELISTED
ObsEva SA Ordinary Shares
OBSV
$12.8K ﹤0.01%
87,999
– –
2017 Q3
21 quarters

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q4 2022 Portfolio in Review

As of Q4 2022, Abingworth held 19 positions worth $307M, up 4.9% from $292M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Abingworth withdrew a net $84.4M in Q4 2022, reducing 1 holding. Its largest reduction was Vaxcyte, cutting an estimated $84.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Abingworth's biggest Q4 2022 reduction was Vaxcyte, cutting an estimated $84.4M.
  • Abingworth's ten largest holdings make up 97% of its $307M portfolio in Q4 2022.
  • Abingworth opened 0 new positions and closed 0 in Q4 2022.
  • Abingworth's portfolio value rose 4.9% quarter-over-quarter to $307M.

Based on Abingworth's 13F filing for Q4 2022, filed 10 Feb 2023.